Dolcanatide Rectal Formulations for Ulcerative Colitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ulcerative colitis, an inflammatory bowel disease, are inadequate as they often rely on corticosteroids and immunomodulators that come with significant side effects and do not provide a cure, necessitating a more effective and side-effect-free therapeutic option.
Innovation Solution
Rectal administration of dolcanatide (SP-333), a guanylate cyclase C (GC-C) agonist, which is administered as an enema or suppository, to alleviate symptoms of ulcerative colitis by stimulating cGMP production and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids and immunomodulators are used to treat ulcerative colitis, then inflammation is reduced and symptoms are relieved, but significant side effects occur and the disease is not cured
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of GC-C agonists through various substitutions and modifications to optimize therapeutic efficacy while minimizing side effects. Different agonist variants are created with specific amino acid changes to achieve the desired balance between effectiveness and safety profile
Solution Approach 2:
The patent uses GC-C agonists as intermediary substances that mediate the treatment of ulcerative colitis by activating the guanylate cyclase C receptor pathway. These agonists serve as intermediaries between the administered drug and the therapeutic effect, triggering a cascade of biochemical events that reduce inflammation without the harmful side effects of traditional treatments
2Productivity
If current ulcerative colitis treatments are used, then symptoms are managed, but no cure is achieved and continuous treatment is required
Solution Approach 1:
The patent applies preliminary action by using GC-C agonists to proactively address the underlying inflammatory mechanisms of ulcerative colitis before symptoms become severe. The treatment aims to prevent disease progression and achieve remission through early and sustained activation of protective physiological pathways
Solution Approach 2:
The patent implements continuity of useful action through formulations designed for sustained release and continuous therapeutic effect. The rectal formulations and dosing regimens are optimized to maintain continuous presence of the agonist at the site of action, ensuring uninterrupted anti-inflammatory activity and preventing symptom recurrence
3Reliability
If rectal formulations of dolcanatide are administered, then treatment effectiveness is improved with minimal side effects, but formulation complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the treatment approach into distinct formulation types (enemas, suppositories, gels) that can be selected based on patient needs and disease severity. Each formulation type is optimized for specific delivery requirements while maintaining the core active ingredient, allowing modular selection without increasing overall system complexity
Solution Approach 2:
The patent employs disposable single-use rectal formulations that eliminate the need for complex storage and handling infrastructure. Each dose is provided in a pre-prepared, sterile, single-use container that is discarded after one use, simplifying the overall system while ensuring treatment safety and efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Dolcanatide effectively reduces symptoms of ulcerative colitis with minimal side effects, as demonstrated by a double-blind study showing significant improvement in patients with mild to moderate ulcerative colitis, indicating its potential as a safe and well-tolerated treatment.
Implementation Method 1
dolcanatide (i.e., SP-333 or SEQ ID NO: 9)... a guanylate cyclase C (GC-C) agonist... by stimulating cGMP production
Data Source
AI summary
This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide.